121 related articles for article (PubMed ID: 25286749)
1. Delayed flare reaction of draining vein due to subcutaneous bortezomib more likely to occur at the inner thigh.
Imataki O; Ota S; Aoyama M; Kubo H; Hamasaki Y; Kida J; Oku M; Uemura M; Ohue Y
Int J Hematol; 2015 Jan; 101(1):99-101. PubMed ID: 25286749
[No Abstract] [Full Text] [Related]
2. Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.
Kamimura T; Miyamoto T; Takashima S; Yokota N; Chong Y; Ito Y; Akashi K
Int J Hematol; 2012 Oct; 96(4):525-7. PubMed ID: 22961216
[No Abstract] [Full Text] [Related]
3. Subcutaneous bortezomib: a step towards optimised drug use.
Mateos MV
Lancet Oncol; 2011 May; 12(5):410-1. PubMed ID: 21507716
[No Abstract] [Full Text] [Related]
4. Bortezomib-induced skin eruption.
Sanchez-Politta S; Favet L; Kerl K; Dietrich PY; Piguet V
Dermatology; 2008; 216(2):156-8. PubMed ID: 18216478
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous lesion induced by a subcutaneous administration of bortezomib.
Obeid KM; Ferrara R; Sharma M
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):284-6. PubMed ID: 22633164
[No Abstract] [Full Text] [Related]
6. Bortezomib: 3 deaths following intrathecal injection.
Prescrire Int; 2012 Sep; 21(130):214. PubMed ID: 23016258
[No Abstract] [Full Text] [Related]
7. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Rekhtman G; Masliak Z; Robak P; Esseltine DL; Feng H; Deraedt W; van de Velde H; Arnulf B
Haematologica; 2015 May; 100(5):e207-10. PubMed ID: 25596270
[No Abstract] [Full Text] [Related]
8. Enhancing care and managing side effects in patients receiving bortezomib.
Colson K
Clin Adv Hematol Oncol; 2006 May; 4(5):6-7; discussion 8; suppl 13. PubMed ID: 16832860
[No Abstract] [Full Text] [Related]
9. Feasibility and efficacy of administration of bortezomib-containing regimens to patients over the age of 70 years.
Parrish C; Cromack J; Feyler S; Ashcroft J; Owen R; Cook G
Br J Haematol; 2011 Apr; 153(2):273-5. PubMed ID: 21275974
[No Abstract] [Full Text] [Related]
10. Lupus tumidus induced by bortezomib not requiring discontinuation of the drug.
Aguayo-Leiva I; Vano-Galvan S; Carrillo-Gijon R; Jaén-Olasolo P
J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1363-4. PubMed ID: 20337821
[No Abstract] [Full Text] [Related]
11. Bortezomib-related diffuse alveolar hemorrhage.
Wirk B
J Clin Oncol; 2012 Dec; 30(36):e379-81. PubMed ID: 23150703
[No Abstract] [Full Text] [Related]
12. Persistent supravenous eruption induced by intravenous bortezomib therapy.
Mataix J; Betlloch I; Palmero F; Romero A
Br J Dermatol; 2008 Apr; 158(4):863-4. PubMed ID: 18284402
[No Abstract] [Full Text] [Related]
13. An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma.
Ohgiya D; Tsuchiya T; Suyama T; Watanabe S; Numata H; Tsuboi K; Sasao T
Acta Haematol; 2015; 133(1):29-30. PubMed ID: 24993672
[No Abstract] [Full Text] [Related]
14. Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study.
Sanchorawala V; Quillen K; Sloan JM; Andrea NT; Seldin DC
Haematologica; 2011 Dec; 96(12):1890-2. PubMed ID: 21859734
[No Abstract] [Full Text] [Related]
15. Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen.
Kamimura T; Miyamoto T; Yokota N; Takashima S; Chong Y; Ito Y; Akashi K
Eur J Haematol; 2013 Feb; 90(2):157-61. PubMed ID: 23240903
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib.
Yokose N; Hirakawa T; Inokuchi K
Leuk Res; 2009 Aug; 33(8):e106. PubMed ID: 19285724
[No Abstract] [Full Text] [Related]
17. Bortezomib administration with severe hyperbilirubinemia caused by hepatic plasma cell infiltration: a case report.
Wilson N; Surati M; Walker BF; Kaufman JL; Harvey RD
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):159-61. PubMed ID: 23084405
[No Abstract] [Full Text] [Related]
18. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Grishunina M; Rekhtman G; Masliak Z; Robak T; Shubina A; Arnulf B; Kropff M; Cavet J; Esseltine DL; Feng H; Girgis S; van de Velde H; Deraedt W; Harousseau JL
Lancet Oncol; 2011 May; 12(5):431-40. PubMed ID: 21507715
[TBL] [Abstract][Full Text] [Related]
19. High incidence and severity of injection site reactions in the first cycle compared with subsequent cycles of subcutaneous bortezomib.
Kamimura T; Miyamoto T; Yokota N; Aoki T; Ito Y; Akashi K
Int J Hematol; 2013 Dec; 98(6):694-701. PubMed ID: 24249047
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
